[1] WHO. World hepatitis day. https://www.who.int/campaigns/world-hepatitis-day. [2020-06-07].
[2] Zhai ZY. An epidemiology study on the distribution of HBsAg and anti-HBs in China. Chin J Microbiol Immunol 1986;20 − 40. (In Chinese).
[3] Dai ZC, Qi GM. Viral hepatitis in China: seroepidemiological survey in Chinese population (part one), 1992−1995. Beijing: Science Press. 1997. http://book.kongfz.com/16076/438904547. (In Chinese).
[4] Liang XF, Bi SL, Yang WZ, Wang LD, Cui G, Cui FQ, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992−2005 in China. J Infect Dis 2009;200(1):39 − 47. http://dx.doi.org/10.1086/599332.
[5] Wang FZ, Zheng H, Liu JH, Sun XJ, Miao N, Shen LP, et al. The coverage of hepatitis A vaccine among 2-29 year olds and the reporting incidence of hepatitis A in China, 2014. Chin J Epidemiol 2016;37(8):1099 − 104. http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2016.08.009. (In Chinese).
[6] National Health Commission of the Peoples’s Republic of China. Notice on issuing the work plan for the prevention of mother-to-child transmission of aids, syphilis and hepatitis B. http://www.nhc.gov.cn/fys/s3581/201102/a0c03b2192a1483384b4f798d9ba603d.shtml. [2020-06-07]. (In Chinese).
[7] National Health Commission of the Peoples’s Republic of China. Notice on preventing mother-to-child transmission of AIDS, syphilis and hepatitis B comprehensively. http://www.nhc.gov.cn/fys/gzbs/201506/4f2123fa955a44afa75a75da2ad35d6e.shtml. [2020-07-06]. (In Chinese).
[8] Li L, Li KY, Yan K, Ou GJ, Li WH, Wang J, et al. The history and challenges of blood donor screening in China. Transfus Med Rev 2017;31(2):89 − 93. http://dx.doi.org/10.1016/j.tmrv.2016.11.001.
[9] National Health Commission of the Peoples’s Republic of China. Notice on issuing the work plan for promoting nucleic acid detection in blood stations (2013-2015) comprehensively. http://www.nhc.gov.cn/yzygj/s3589/201305/d1f4685531df4284a6603756b83576b8.shtml. [2020-07-06]. (In Chinese).
[10] Ministry of Health of the Peoples’s Republic of China. National Hepatitis B prevention and treatment planning, 2006-2010. http://www.gov.cn/gzdt/2006-02/13/content_187608.htm. [2020-07-09]. (In Chinese).
[11] National Health Commission of the Peoples’s Republic of China. National hepatitis B prevention and treatment planning, 2017-2020. http://www.nhc.gov.cn/ewebeditor/uploadfile/2017/11/20171113134002475.pdf. [2020-07-06]. (In Chinese).
[12] Cui FQ, Shen LP, Li L, Wang HQ, Wang FZ, Bi SL, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis 2017;23(5):765 − 72. http://dx.doi.org/10.3201/eid2305.161477.
[13] National Healthcare Security Administration of the Peoples’s Republic of China. Notice on incorporating negotiated medicines in 2019 in category B of the national medicines catalogue of basic medical insurance, industrial injury insurance and maternity insurance. http://www.gov.cn:8080/xinwen/2019-11/28/content_5456662.htm. [2020-07-06]. (In Chinese).
[14] González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol 2016;22(4):1421 − 32. http://dx.doi.org/10.3748/wjg.v22.i4.1421.
[15] Wang FZ, Sun XJ, Wang F, Zheng H, Jia ZY, Zhang GM, et al. Changing epidemiology of hepatitis a in China: evidence from three national serological surveys and the national notifiable disease reporting system. Hepatology 2020. http://dx.doi.org/10.1002/hep.31429.